No frank overdose has occurred in any patient to date. Sandostatin® (octreotide acetate) Injection given in intravenous bolus doses of 1 mg (1000 mcg) to healthy volunteers did not result in serious ill effects, nor did doses of 30 mg (30,000 mcg) given IV over 20 minutes and of 120 mg (120,000 mcg) given IV over 8 hours to research patients. Doses of 2.5 mg (2500 mcg) of Sandostatin® Injection subcutaneously have, however, caused hypoglycemia, flushing, dizziness, and nausea.
Up-to-date information about the treatment of overdose can often be obtained from a certified Regional Poison Control Center. Telephone numbers of certified Regional Poison Control Centers are listed in the Physicians' Desk Reference ® *.
Mortality occurred in mice and rats given 72 mg/kg and 18 mg/kg IV, respectively, of octreotide.
DRUG ABUSE AND DEPENDENCE
There is no indication that octreotide has potential for drug abuse or dependence. Octreotide levels in the central nervous system are negligible, even after doses up to 30,000 mcg.